A first-in-class gene-regulating therapy cut seizures by up to 91% in children with Dravet syndrome in extension studies, ...

A Phase I/IIa clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that ...

STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is ...

Groundbreaking Phase 1/2a clinical trials co-led by Linda Laux, MD, from Ann & Robert H. Lurie Children's Hospital of Chicago, show that the first gene regulation treatment for epilepsy is safe and ...

A doctor at Lurie Children's Hospital is co-leading clinical trials for a treatment that targets the genetic cause of Dravet syndrome. If approved, the medication would become the first gene ...

Scientists from the Allen Institute and Seattle Children’s Research Institute have announced a breakthrough in the development of gene replacement therapies for Dravet syndrome, a rare form of ...

SEATTLE, Wash. -- Scientists at the Allen Institute have made a major breakthrough in research for people living with Dravet Syndrome, which is a rare and debilitating form of epilepsy that starts ...

For families of children with Dravet syndrome who have exhausted conventional treatment options, new hope is emerging.A first‑ever gene‑regulation ...